Zurampic

Hyperuricemia, Arthritis, Gouty

Treatment

3 FDA approvals

4 Active Studies for Zurampic

What is Zurampic

Lesinurad

The Generic name of this drug

Treatment Summary

Lesinurad (marketed as Zurampic and Duzallo) is a medication used to lower uric acid levels in people with gout who have not been able to lower their uric acid levels with a xanthine oxidase inhibitor alone. It works by blocking the enzymes responsible for absorbing uric acid from the kidneys. Lesinurad is FDA-approved for use in combination with a xanthine oxidase inhibitor and can be prescribed under the brand name Duzallo.

Zurampic

is the brand name

Zurampic Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zurampic

Lesinurad

2016

4

Approved as Treatment by the FDA

Lesinurad, otherwise known as Zurampic, is approved by the FDA for 3 uses which include Hyperuricemia and Hyperuricemia .

Hyperuricemia

Used to treat Hyperuricemia in combination with null

Hyperuricemia

Used to treat Hyperuricemia in combination with null

Arthritis, Gouty

Used to treat Gouty Arthritis in combination with null

Effectiveness

How Zurampic Affects Patients

Taking lesinurad regularly will gradually lower the amount of uric acid in the blood, and cause more uric acid to be passed in urine.

How Zurampic works in the body

Lesinurad works by blocking two transporter enzymes, URAT1 and OAT4. URAT1 is responsible for bringing uric acid into the body, so blocking it increases the amount of uric acid that is removed from the body.

When to interrupt dosage

The advised dose of Zurampic is contingent upon the diagnosed condition. The amount of dosage fluctuates according to the administration technique (e.g. Tablet, film coated - Oral or Tablet, film coated) as stated in the table below.

Condition

Dosage

Administration

Arthritis, Gouty

200.0 mg,

Tablet, film coated, Tablet, film coated - Oral, Oral,

Hyperuricemia

200.0 mg,

Tablet, film coated, Tablet, film coated - Oral, Oral,

Warnings

Zurampic has six contraindications and should not be employed in combination with the afflictions listed in the subsequent table.

Zurampic Contraindications

Condition

Risk Level

Notes

Lesch-Nyhan Syndrome

Do Not Combine

Tumor Lysis Syndrome

Do Not Combine

Renal Transplant Recipient Patients

Do Not Combine

Kidney Failure

Do Not Combine

on dialysis

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Zurampic.

Common Zurampic Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Lesinurad.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Lesinurad.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be increased when combined with Lesinurad.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Lesinurad.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Lesinurad.

Zurampic Novel Uses: Which Conditions Have a Clinical Trial Featuring Zurampic?

Three clinical trials are currently underway to evaluate the potential of Zurampic in alleviating Gouty Arthritis.

Condition

Clinical Trials

Trial Phases

Arthritis, Gouty

0 Actively Recruiting

Hyperuricemia

3 Actively Recruiting

Phase 3, Phase 1

Patient Q&A Section about zurampic

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is ZURAMPIC used for?

"ZURAMPIC should be taken with a xanthine oxidase inhibitor in order to lower uric acid levels in the blood for adult patients with gout."

Answered by AI

What is the drug probenecid used for?

"Probenecid is used to treat chronic gout or gouty arthritis by removing excess uric acid from the body, though it does not cure gout. After taking probenecid for a few months, it will help prevent gout attacks."

Answered by AI

Why was lesinurad discontinued?

"- The FDA has announced that Ironwood Pharmaceuticals will no longer be producing Duzallo (lesinurad/allopurinol) and Zurampic (lesinurad). The discontinuation is due to business reasons and not because of any safety, efficacy, or quality issues."

Answered by AI

What is probenecid used for?

"Probenecid is a medication used to treat chronic gout or gouty arthritis by removing excess uric acid from the body. Although probenecid does not cure gout, it can help prevent gout attacks after a few months of use."

Answered by AI

What class of drug is lesinurad?

"Lesinurad is a medication that helps the kidneys remove uric acid from the body."

Answered by AI

Clinical Trials for Zurampic

Image of PAREXEL International - Early Phase Clinical Unit Baltimore in Baltimore, United States.

NNC4004-0002 for High Uric Acid

35 - 75
All Sexes
Baltimore, MD

This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.

Phase 1
Recruiting

PAREXEL International - Early Phase Clinical Unit Baltimore (+2 Sites)

Clinical Transparency (dept. 2834)

Novo Nordisk A/S